SunRock Biopharma and GenScript ProBio to develop new monoclonal antibody program

Tuesday, February 23, 2021

GenScript ProBio and SunRock Biopharma, a company focused on developing cancer-targeted antibody therapeutics, announced a collaboration spanning preclinical discovery for large-scale GMP manufacturing for SunRock's CCR9 therapeutic antibody candidates. GenScript ProBio will offer SunRock Biopharma an all-in-one solution from antibody discovery, cell line development, process development to GMP drug product and drug substance manufacturing services.

Leveraging complementary strengths and capabilities, the parties engage with R&D, manufacturing process development, IND submissions to the NMPA, FDA, and EMA of CCR9 therapeutic antibodies, toward the rapid development of new antibody therapeutics.

CCR9 is a new therapeutic target expressed in highly aggressive cancer. It is associated with increased metastatic potential and tumor chemoresistance. This program will allow new formats of treatment with innovative monoclonal antibody drugs of different solid tumors and blood neoplasia with a highly unmet clinical need, such as T-cell acute lymphoblastic leukemia or pancreatic cancer.  

"Collaborating with GenScript ProBio and having access to their excellent production methods will allow us to accelerate the delivery of our antibodies to patients who need new approaches to treatment. We aim to start clinical trials in June 2022 and collaborate with a relevant partner such as GenScript. ProBio will be key to achieving our goal, "said Juan Buela , CEO of SunRock.

"We are delighted to be collaborating with SunRock Biopharma to accelerate their preclinical CCR9 therapeutic antibody program. Innovation through collaboration is the vision of GenScript ProBio. GenScript ProBio will make it easier for SunRock Biopharma to expand its line of innovative antibody products. Committed to" deliver the best quality and serve customer interests, "GenScript ProBio works to expedite pharmaceutical transformation. Through collaboration, we will explore and shape the landscape of next-generation differentiated immunotherapy for cancers. With our expertise in cancer services CMC and GMP manufacturing along with support from SunRock Biopharma, an innovative biopharmaceutical company, we hope that more patients will benefit from superior treatments, "said Dr.Brian Min , CEO of GenScript ProBio.

Latest Issue
Get instant
access to our latest e-book
Eppendorf - BioFlo® 720